Dongze Li1, Wei Wei1, Xun Ran2, Jing Yu1, Hui Li3, Lizhi Zhao4, Honglian Zeng5, Yu Cao1, Zhi Zeng1, Zhi Wan6. 1. Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, China. 2. Department of Cardiology, Chengdu Shangjin Nanfu Hospital, Chengdu, China. 3. Department of Internal Medicine, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. 4. Department of Cardiology, Second Affiliated Hospital of Southwest Medical University, Luzhou, China. 5. Department of Geriatric, Affiliated Hospital of Chengdu University, Chengdu, China. 6. Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, China. Electronic address: 303680215@qq.com.
Abstract
BACKGROUND: This study investigated the associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and the risks of coronary heart disease (CHD) and ischemic stroke (IS) in the general population. METHODS: PubMed, Embase, and the Cochrane Library databases were searched for prospective cohort studies published prior to June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for CHD and IS risks according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using random-effects modeling. RESULTS: Twelve studies examining Lp-PLA2 activity or mass and long-term risks of CHD and IS were included. Combined HRs for CHD and IS risks for the highest category referring to lowest category of Lp-PLA2 were 1.46 (95% CI: 1.20-1.78, P<0.001) and 1.58 (95% CI: 1.21-2.07, P=0.001), respectively. The same patterns were observed for both mass and activity, with the exception of those for CHD. For every 1-standard deviation (SD) increase in Lp-PLA2 activity, CHD risk increased by 12% (HR: 1.12, 95% CI: 1.05-1.22, P=0.002); no association between 1-SD increases in Lp-PLA2 activity and IS was observed. Lp-PLA2 mass was associated with CHD risk (HR: 1.02-1.24, 95% CI: 1.02-1.24, P=0.021). Lp-PLA2 mass per 1-SD increase was not associated with IS risk. CONCLUSIONS: Greater Lp-PLA2 activity or mass was associated with an increased risk of CHD and IS; however, additional well-designed trials are warranted to confirm this association.
BACKGROUND: This study investigated the associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and the risks of coronary heart disease (CHD) and ischemic stroke (IS) in the general population. METHODS: PubMed, Embase, and the Cochrane Library databases were searched for prospective cohort studies published prior to June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for CHD and IS risks according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using random-effects modeling. RESULTS: Twelve studies examining Lp-PLA2 activity or mass and long-term risks of CHD and IS were included. Combined HRs for CHD and IS risks for the highest category referring to lowest category of Lp-PLA2 were 1.46 (95% CI: 1.20-1.78, P<0.001) and 1.58 (95% CI: 1.21-2.07, P=0.001), respectively. The same patterns were observed for both mass and activity, with the exception of those for CHD. For every 1-standard deviation (SD) increase in Lp-PLA2 activity, CHD risk increased by 12% (HR: 1.12, 95% CI: 1.05-1.22, P=0.002); no association between 1-SD increases in Lp-PLA2 activity and IS was observed. Lp-PLA2 mass was associated with CHD risk (HR: 1.02-1.24, 95% CI: 1.02-1.24, P=0.021). Lp-PLA2 mass per 1-SD increase was not associated with IS risk. CONCLUSIONS: Greater Lp-PLA2 activity or mass was associated with an increased risk of CHD and IS; however, additional well-designed trials are warranted to confirm this association.
Authors: Andreana De Mauri; Deborah Carrera; Marco Bagnati; Roberta Rolla; Matteo Vidali; Doriana Chiarinotti; Marco Pane; Angela Amoruso; Mario Del Piano Journal: Nutrients Date: 2022-04-14 Impact factor: 6.706